A review of advances in biologic therapy for Beh?et uveitis

VernacularTitle:生物制剂治疗Beh?et病葡萄膜炎的研究进展
Author: Biao LI ¹ ; Haoran LI ; Hui HUANG ; Yanlin ZHENG
Author Information

1. 成都中医药大学附属医院眼科　610032
Keywords: Behcet syndrome; Uveitis; Biological agents; Review
From: Chinese Journal of Ocular Fundus Diseases 2021;37(9):737-742
CountryChina
Language:Chinese
Abstract: Beh?et uveitis (BU), one of the common manifestations of Beh?et syndrome, has a poor prognosis, high blinding rate, and severely impairs the quality of patients' life. The current treatment principle mainly induce and maintain inflammation remission by suppressing the immune response. The glucocorticoid combined with immunosuppressive therapy for the treatment of BU has disadvantages such as long medication time, severe adverse effects, and poor long-term prognosis, whereas biologics have gradually attracted attention about the treatment of BU because of their high efficacy, low toxicity, and good long-term prognosis. The biologics used to treat BU include tumor necrosis factor-α inhibitors, interferon-α, interleukin blockers, and lymphocyte targeting preparations. It is believed that with the progress of various studies and clinical trials, the stepwise application of biologics is promising, and it is hopeful to provide more accurate and effective treatment for patients with BU in the future.